Compare VPG & OPK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VPG | OPK |
|---|---|---|
| Founded | 2009 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 968.7M | 1.0B |
| IPO Year | 2010 | 2011 |
| Metric | VPG | OPK |
|---|---|---|
| Price | $74.19 | $1.56 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $93.33 | $4.38 |
| AVG Volume (30 Days) | 255.8K | ★ 2.2M |
| Earning Date | 11-03-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $307,202,000.00 | ★ $606,879,000.00 |
| Revenue This Year | $12.08 | N/A |
| Revenue Next Year | $7.69 | $3.35 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 0.22 | N/A |
| 52 Week Low | $29.08 | $0.98 |
| 52 Week High | $151.78 | $1.75 |
| Indicator | VPG | OPK |
|---|---|---|
| Relative Strength Index (RSI) | 55.97 | 52.14 |
| Support Level | $59.70 | $1.46 |
| Resistance Level | $76.58 | $1.61 |
| Average True Range (ATR) | 2.98 | 0.05 |
| MACD | 1.73 | -0.01 |
| Stochastic Oscillator | 89.85 | 28.57 |
Vishay Precision Group Inc manufactures and markets sensors and sensor-based measurement systems, as well as specialty resistors and strain gages based on proprietary technology. The company provides precision products and solutions, many of which are designed-in by customers, specializing in the growing markets of stress, force, weight, pressure, and current measurements. The company reports in three product segments: Sensors segment, Weighing Solutions segment, and Measurement Systems segment. It has a business presence in the United States and other countries. It generates the maximum of its revenue from the United States.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.